Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Seattle Biomedical Research Institute
ClinicalTrials.gov Identifier:
NCT01024686
First received: December 1, 2009
Last updated: May 28, 2013
Last verified: May 2013